Abstract
Gp130 cytokines are involved in the regulation of numerous biological processes, including hematopoiesis, immune response, inflammation, cardiovascular action, and neuronal survival. These cytokines share glycoprotein 130 as a common signal transducer in their receptor complex and typically activate STAT3. Most gp130 cytokines have paracrine or endocrine actions, and their levels can be measured in circulation in rodents and humans. In recent years, various laboratories have conducted studies to demonstrate that gp130 cytokines can modulate adipocyte development and function. Therefore, these studies suggest that some gp130 cytokines may be viable anti-obesity therapeutics. In this review, we will summarize the reported effects of gp130 cytokines on adipocyte differentiation and adipocyte function. In addition, the modulation of gp130 cytokines in conditions of obesity, insulin resistance, and Type 2 diabetes will be presented.
Current Pharmaceutical Design
Title: The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Volume: 17 Issue: 4
Author(s): Ursula A. White and Jacqueline M. Stephens
Affiliation:
Keywords: Adipocyte, gp130, STAT3, IL-6, OSM, LIF, CT-1
Abstract: Gp130 cytokines are involved in the regulation of numerous biological processes, including hematopoiesis, immune response, inflammation, cardiovascular action, and neuronal survival. These cytokines share glycoprotein 130 as a common signal transducer in their receptor complex and typically activate STAT3. Most gp130 cytokines have paracrine or endocrine actions, and their levels can be measured in circulation in rodents and humans. In recent years, various laboratories have conducted studies to demonstrate that gp130 cytokines can modulate adipocyte development and function. Therefore, these studies suggest that some gp130 cytokines may be viable anti-obesity therapeutics. In this review, we will summarize the reported effects of gp130 cytokines on adipocyte differentiation and adipocyte function. In addition, the modulation of gp130 cytokines in conditions of obesity, insulin resistance, and Type 2 diabetes will be presented.
Export Options
About this article
Cite this article as:
A. White Ursula and M. Stephens Jacqueline, The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function, Current Pharmaceutical Design 2011; 17 (4) . https://dx.doi.org/10.2174/138161211795164202
DOI https://dx.doi.org/10.2174/138161211795164202 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Withdrawal Notice: COVID-19: Outbreak to Global
Anti-Infective Agents Effects of Tea Catechins on Inflammation-Related Cardiovascular Diseases
Current Immunology Reviews (Discontinued) Microcirculation and Heart Failure
Current Pharmaceutical Design Administration of Exogenous Surfactant and Cytosolic Phospholipase A2α Inhibitors may Help COVID-19 Infected Patients with Chronic Diseases
Coronaviruses The Role of Trimetazidine After Acute Myocardial Infarction
Current Vascular Pharmacology Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design Immunomodulatory Gene Therapy in Lysosomal Storage Disorders
Current Gene Therapy Abietane Diterpenes as Potential Candidates for the Management of Type 2 Diabetes
Current Pharmaceutical Design Organoselenium Compounds as Potential Therapeutic and Chemopreventive Agents: A Review
Current Medicinal Chemistry Natural Alkaloids and Diabetes Mellitus: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
Current Drug Targets Matrix Metalloproteinases: Drug Targets for Myocardial Infarction
Current Drug Targets Diagnostic Value of HLA Typing in Pathogenesis of Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Utility of Anti-Arrhythmic Medications in ‘Lone Atrial Fibrillation’
Current Pharmaceutical Design Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes
Current Pharmaceutical Biotechnology Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons
Current Cardiology Reviews Impact of Pulmonary Vascular Resistances in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules
Inflammation & Allergy - Drug Targets (Discontinued) Reactive Oxygen Species in Myocardial Reperfusion Injury: From Physiopathology to Therapeutic Approaches
Current Pharmaceutical Biotechnology Mediterranean Diet, Brain and Muscle: Olive Polyphenols and Resveratrol Protection in Neurodegenerative and Neuromuscular Disorders
Current Medicinal Chemistry